Sterling Pharma Solutions

Sterling Pharma Solutions is a rapidly growing, globally integrated Contract Development and Manufacturing Organization (CDMO) that specializes in delivering advanced API development and manufacturing services. Headquartered in Cramlington, United Kingdom, Sterling has strategically expanded its footprint with state-of-the-art facilities across the UK, Europe, and the United States.

The company is particularly renowned for its deep expertise in handling complex and hazardous chemistry, which many other manufacturers are not equipped to manage. This includes high-pressure reactions, cryogenic processes, and the safe handling of highly potent APIs (HPAPIs). In recent years, Sterling has aggressively invested in advanced bioconjugation technologies and Antibody-Drug Conjugate (ADC) capabilities, positioning itself at the cutting edge of targeted oncology therapies.

Sterling is also a recognized industry leader in continuous flow chemistry, investing heavily in technology that makes chemical synthesis safer, more scalable, and environmentally sustainable compared to traditional batch processing. Their partnership model is highly collaborative, focusing on seamless technology transfer and robust process engineering to take client molecules from the laboratory bench through clinical trials and into commercial production.

The organization places a paramount emphasis on Quality, Health, Safety, and Environment (QHSE), ensuring rigorous compliance with MHRA, US FDA, and EMA standards. By combining niche chemical capabilities with a strong culture of scientific problem-solving, Sterling Pharma Solutions acts as a crucial catalyst for bringing next-generation therapeutics to the global market.